While constructs combining CD3, CD19 or CD22, and CD28 have demonstrated enhanced efficacy in high-burden ALL models in vitro, no clinical-stage CD28-containing trispecifics for ALL have been developed to date [45,46]. This evidence concerns the gene CD28 and acute lymphoblastic leukemia.